Plain-English translation of NCT05077527 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing , an immune cell therapy designed to fight aggressive B-cell lymphoma in people living with HIV. The treatment works by taking your own immune cells, specially engineering them in a laboratory to recognize and attack cancer cells, and then returning them to your body. Researchers want to see if this treatment is safe and effective for people whose lymphoma has come back or stopped responding to previous therapies.
Aggressive B-cell lymphoma in people with HIV can be difficult to treat, especially when it returns or stops responding to standard chemotherapy. This trial exists to find out whether this new cell-based therapy offers hope for patients who have limited options left.
You likely qualify if…
You likely don't qualify if…
You will receive chemotherapy medications ( and ) over three days to prepare your body. Then you will receive one infusion of the engineered immune cells. After treatment, you'll have frequent follow-up visits: weekly for the first month, monthly for months 2–6, and then at 9, 12, 15, 18, and 24 months to monitor how well the treatment works and watch for any side effects. The trial will involve blood tests, scans, and check-ins with your medical team throughout this period.
AI-generated summary from trial data · Jul 16, 2026 · Not medical advice
United States